A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

Multiple Myeloma Clinical Trial

Official title:

A Two Part Phase 1 Multicenter Open-label Study of DKN-01 Given Intravenously. Part A: Dose-Escalation in Patients With Multiple Myeloma or Advanced Solid Tumors. Part B: Expansion Cohort in Patients With Relapsed / Refractory Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01457417
• Other study ID #: P100
• Secondary ID: DEK-DKK1-P100LY2
• Status: Completed
• Phase: Phase 1
• First received: October 18, 2011
• Last updated: September 26, 2016
• Start date: January 2012
• Est. completion date: December 2013

Study information

• Verified date: September 2016
• Source: Leap Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer. To characterize the pharmacokinetic parameters of DKN-01 in cancer patients who are intolerant to standard/approved therapies.

Description:

Part A of this trial consists of 4 treatment arms of DKN-01. It is a dose escalation study in patients with multiple myeloma or advanced solid tumors. Patients must be refractory or intolerant to all standard/approved therapy(ies). At each dose level, 3 subjects will be treated. If none of the 3 subjects develop a dose limiting toxicity after a minimum of 4 weeks of treatment, subsequent dose escalation will proceed according to the same schedule. Part B consists of dose confirmation in patients with NSCLC. Patients must be refractory or intolerant to all standard/approved therapy(ies). Approximately 15 patients may be enrolled in Part B.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

Part A: Patients with histological or cytological confirmed multiple myeloma or advanced solid tumors. For multiple myeloma, must have symptomatic myeloma as defined by the International Myeloma Working Group inclusive of measurable serum and/or urine monoclonal protein (M-protein) or for those without elevations they must have measurable increased concentrations of free light chains

Part B: Patients with previously treated, histologically confirmed advanced NSCLC with progressive disease requiring therapy

Parts A and B:

• Refractory or intolerant to all standard/approved therapy(ies)

• Patients with solid tumors must have one or more metastatic tumors measurable on computed tomography (CT) scan using Response Evaluation Criteria in Solid Tumors (RECIST) criteria

• Radiation for symptomatic lesions outside the central nervous system (CNS) must have been completed at least 2 week prior to study enrollment

• Treated brain metastases will be allowed, if they are asymptomatic. Patients must be off corticosteroids for at least 2 week prior to study entry

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1

• Life expectancy of at least 3 months

• Ambulatory patients greater than or equal to (=) 30 years of age

• Females with child bearing potential must have a negative serum pregnancy test within 7 days of study entry

• Acceptable liver function, renal function, hematologic status

• Urinalysis - No clinically significant abnormalities

• Acceptable coagulation status:

• Prothrombin Time/Partial Thromboplastin Time (PT/PTT) = 1.2 x upper limit of normal (ULN) (unless receiving anticoagulation therapy - eligibility based upon INR)

• International Normalization Ratio (INR) = 1.6 (unless receiving anticoagulant therapy)

• Receiving warfarin; INR = 3.0 and no active bleeding

• For men and women of child-producing potential, the use of effective contraceptive methods during the study and for women 18 months following the last dose of study drug

• Available for the study duration and willing to follow procedures

• Serum calcium:

• Solid tumors only: within normal limits

• Multiple myeloma: = 11.5 milligrams per deciliter (mg/dL)

Exclusion Criteria:

• History of osteonecrosis of the hip or evidence of structural bone abnormalities in the proximal femur on magnetic resonance imaging (MRI) scan considered clinically significant or may impact the interpretation of the scan. Degenerative changes of the hip joint are not exclusionary

• Unable to tolerate the confinement/noise of an MRI scanner or have any contraindication for MRI

• New York Heart Association Class 3 or 4, cardiac disease, myocardial infarction, unstable arrhythmia, or evidence of ischemia

• Have Fridericia-corrected QT interval (QTcF) > 470 millisecond (msec) (female) or > 450 (male), or history of congenital long QT syndrome.

• Active, uncontrolled bacterial, viral, or fungal infections

• Pregnant or nursing women

• Radiation therapy, surgery, or chemotherapy, within 1 month prior to study entry

• Previously treated with an anti-Dickkopf-related protein 1 (DKK-1) therapy

• Significant allergy to a biological pharmaceutical therapy

• History of major organ transplant

• Had an autologous or allogenic bone marrow transplant, current acute leukemia, colon, prostate, breast or small cell lung cancer, osteoblastic lesions, concomitant disease known to influence calcium metabolism including hyperparathyroidism, hyperthyroidism and/or Paget's disease of bone

• Unwillingness / inability to comply with procedures

• Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

• Serious nonmalignant disease

• Receiving other investigational agent or have received other investigational agent within last 30 days or 5 half-lives, whichever is longer

• Receiving lithium chloride (LiCl)

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Multiple Myeloma
• Neoplasms, Plasma Cell
• Non-Small Cell Lung Cancer
• Solid Tumors

Intervention

Drug:
• DKN-01
DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.

Locations

Country	Name	City	State
United States	New York Oncology Hematology, P.C.	Albany	New York
United States	Texas Oncology - Baylor, Charles A. Sammonds Cancer Center	Dallas	Texas
United States	Greenville Hospital System University Medical Center	Greenville	South Carolina
United States	Virginia Oncology Associated	Norfolk	Virginia
United States	Virginia Commonwealth University - Massey Cancer Center	Richmond	Virginia
United States	Scottsdale Healthcare	Scottsdale	Arizona
United States	Texas Oncology - Tyler	Tyler	Texas
United States	Northwest Cancer Specialists, P.C.	Vancouver	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Leap Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Summary of Total Adverse Events (AE)	Total Adverse Events (AE), total treatment emergent adverse events (TEAE), total Serious Adverse Events (SAE), and total dose-limiting toxicity (DLT) for both Parts A and B.	Baseline to study completion (approximately 3 months)	Yes
Primary	Summary of Patients With Adverse Events (AE)	Number of patients who had Adverse Events (AE) including treatment related treatment emergent adverse events (TEAE), Common Toxicity Criteria for Adverse Effects (CTCAE), and Serious Adverse Events (SAE) for both Parts A and B. Severity was coded to NCI CTCAE version 4.02. For maximum severity and relationship, patients were counted only once in the most severe or most related category.	Baseline to study completion (approximately 3 months)	Yes
Primary	Progression Free Survival (PFS) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)	For Part B only. The distribution of PFS was estimated using the Kaplan-Meier (KM) method. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (ie, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.	Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause	No
Secondary	Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01	Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.	Cycle 1 Day 1 (first dose, all groups)	No
Secondary	Pharmacokinetics: Area Under the Concentration - Time Curve (AUC) of DKN-01	Area under the DKN-01 serum concentration-time profile curve during the dosing interval (AUC0-tau) after the first and fourth infusion for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.	Cycle 1 Day 22 (Fourth Dose for QW)	No
Secondary	Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01	Peak DKN-01 serum concentration (Cmax) after the first and fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 Day 1 included once per week (QW) dosing groups and every two weeks (Q2W) dosing groups.	Cycle 1 Day 1 (first dose, all groups)	No
Secondary	Pharmacokinetic: Maximum Plasma Concentration (Cmax) of DKN-01	Peak DKN-01 serum concentration (Cmax) after the fourth infusion on Cycle 1 Weeks 1 and 4, for both Parts A and B. Cycle 1 day 22 included only QW dosing groups.	Cycle 1 Day 22 (Fourth dose for QW groups)	No
Secondary	Progression Free Survival (PFS) in Patients Who Are Refractory or Intolerant to Standard/Approved Therapies	For both Parts A and B. PFS was defined as the time from the date of signed informed consent to the first date of objectively determined progressive disease (Progression is defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) and International Multiple Myeloma Working Group (IMWG)) or death from any cause. For patients who were still alive at the time of analysis (i.e, data cut-off date) and without evidence of tumor progression, PFS was censored at the date of the most recent objective progression-free observation.	Time from the date of signed informed consent to the first date of objectively determined progressive disease or death from any cause	No
Secondary	Overall Survival (OS) in Patients With Relapsed or Refractory NSCLC	For Part B only. OS was defined as the time from the date of signed informed consent to the date of death from any cause. For patients who were still alive as of the data cut-off date, OS time was censored on the date of the patient's last contact (last contact for patients in post-discontinuation was the last date of contact in long-term follow-up eCRF).	Time from the date of signed informed consent to the date of death from any cause	No
Secondary	Objective Response Rate (ORR) in Oncologic Patients Who Are Refractory or Intolerant to Standard/Approved Therapies	For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)	Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter	No
Secondary	Objective Response Rate (ORR) in Patients With Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC)	FAS : For both Parts A and B. Objective response rate is defined as the number of patients with overall best response of complete response (CR) or partial response (PR)	Part A: Every 2 months; Part B: after 1 month and every two cycles thereafter	No